Impact of a rural village women (Asha) intervention on adherence to antiretroviral therapy in southern India.
Adeline Nyamathi, Alecia Y Hanson, Benissa E Salem...
https://pubmed.ncbi.nlm.nih.gov/22872107/Actively Recruiting
Led by University of California, Irvine · Updated on 2026-07-31
348
Participants Needed
4
Research Sites
N/A
Total Duration
Cervical cancer is a significant health issue among women in India, especially those living with both human papillomavirus HPV and human immunodeficiency virus HIV. Women living with HIV have a higher risk of persistent high-risk HPV infection, which can lead to cervical cancer. Factors such as lack of HPV screening, depression, stigma, and malnutrition worsen this risk. This study aims to evaluate a nurse-led, peer counselor-supported nutrition-enhanced intervention called SAKHI HPV, designed to prevent cervical cancer among women co-infected with HPV and HIV. The study is a five-year randomized controlled trial comparing the SAKHI HPV intervention to an enhanced standard of care SOC. The SAKHI intervention includes eight group education sessions led by healthcare experts, weekly one-on-one peer counselor support, and referral to life skills training classes. The SOC group receives usual care plus three group sessions on wellness, nutrition, and HIVHPV health promotion. Participants are women living with HIV who test positive for HPV but negative on visual inspection with acetic acid VIA. The intervention lasts six months, with follow-up assessments at 6, 12, and 18 months. Participants undergo screening with self-collected HPV swabs and VIA tests. Those eligible are randomized to either study arm. Throughout the study, questionnaires on demographics, stigma, mental health, diet, and adherence are collected. Blood tests measure nutritional markers, CD4 count, and HIV viral load. Peer counselors maintain regular contact to support adherence and engagement. The primary outcome is persistence of high-risk HPV infection measured over 12 to 18 months. Secondary outcomes include changes in HIV viral load, CD4 count, and serum albumin levels. The total participation period is 18 months after enrollment.
CONDITIONS
Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India
V
Veena Satyanarayana
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of California, Irvine
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility, including HIV status, HPV testing with self-collected vaginal swabs, and VIA screening.
1 visit for screening and sample collection
Duration - 6 months
Participants receive either the SAKHI intervention with group sessions, weekly peer counselor support, and life skills training, or the enhanced standard of care with fewer group sessions and less individual support.
Weekly peer counselor visits and group sessions bimonthly for four months, then monthly role play sessions for two months
Duration - 12 months after intervention ends
Participants complete follow-up assessments at 6, 12, and 18 months including questionnaires, blood tests, nutrition assessments, and immune function tests.
Assessments at 6, 12, and 18 months post-baseline
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Adeline Nyamathi, Alecia Y Hanson, Benissa E Salem...
https://pubmed.ncbi.nlm.nih.gov/22872107/Dana Rose Garfin, Sanghyuk S Shin, Maria L Ekstrand...
https://pubmed.ncbi.nlm.nih.gov/30714386/Adeline Nyamathi, Maria Ekstrand, Benissa E Salem...
https://pubmed.ncbi.nlm.nih.gov/23539322/Adeline Nyamathi, Maria Ekstrand, Neha Srivastava...
https://pubmed.ncbi.nlm.nih.gov/26147930/University of California, Irvine
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor